TR-701 Phase 1 Clinical Trial Results Disclosed
SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing "Best-in-Class" drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead program, TR-701, and its other pipeline programs will be presented in eighteen presentations at the upcoming joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) meeting in Washington, DC. Thirteen of the presentations focus on TR-701, a second generation oxazolidinone that recently commenced Phase 2 clinical studies.
"Acceptance of these presentations by the ICAAC committee highlights the interest in and value of the TR-701 program, the Trius pipeline, and our underlying technologies," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are especially pleased to provide details of our TR-701 Phase 1 clinical trial results that support the once-daily dosing and short course of therapy in our recently initiated Phase 2 study in complicated skin and skin structure infections (cSSSIs). It is also exciting to see that the results of studies by external investigators demonstrate the drug's increased potency and expanded spectrum of activity."
The presentations are as follows:
Saturday, October 25th
(Poster Summary Session, Ballroom A/B, 10:00 am - 12:00 pm)
-- Oral Presentation: Overview of TR-701 and TR-700 Posters and
(Poster Session 23, 12:15 pm - 1:15 pm)
-- F1-334: Discovery and SAR of a Novel Series of Pyrimidine Antibacterials
Targeting Methionyl-tRNA Synthase (MetRS)
-- F1-335: In Vitro Activity of Rx100472 Against Clinically Important
-- F1-336: Advanced Microbiology Study of Rx100472, A Novel Methionyl-tRNA
Synthetase (MetRS) inhibi
|SOURCE Trius Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved